HEPATOCELLULAR CARCINOMA AND HEPATITIS C: E2 MOLECULAR MECHANISMS
HEPATOCELLULAR CARCINOMA AND HEPATITIS C: E2 MOLECULAR MECHANISMS
批准号:
7470415
负责人:
MARTINA BUCK
金额:
$14.88万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-07-01 至 2011-06-30
关键词:
1-Phosphatidylinositol 3-KinaseActinsAdaptor Signaling ProteinAmino Acid MotifsBiological AssayBiological ModelsBlocking AntibodiesClathrinClathrin AdaptorsCo-ImmunoprecipitationsDNA Replication InductionDNA biosynthesisDataDominant-Negative MutationEGF geneEndocytosisFamilyGlycoproteinsGrowth FactorHepatitisHepatitis CHepatitis C virusHepatocarcinogenesisHepatocyteHumanIn VitroIndividualInfectionLife Cycle StagesLiverMediatingModelingMolecularPDPK1 genePathway interactionsPatientsPeptidesPhosphatidylinositol 4,5-DiphosphatePhosphoinositide-3-Kinase, Catalytic, Gamma PolypeptidePhosphorylationPhosphotransferasesPhysiologicalPrimary carcinoma of the liver cellsResearch PersonnelRoleSignal TransductionSiteStaining methodStainsSystemTertiary Protein StructureTransfectionTumor PromotersViralVirusextracellularhepatitis C virus envelope 2 proteinliver cell proliferationmembernovelparticleprogramsreceptor mediated endocytosisvirology
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Central Hypothesis: The Hepatitis C Virus (HCV) E2 glycoprotein is a novel kinase that initiates signal transduction mechanisms modulating the following pathways: 1.) Clathrin-mediated endocytosis, through a site-specific phosphorylation of the clathrin adaptor protein-50 (AP50), a key regulator of clathrin-mediated receptor endocytosis; and 2.) Hepatocyte proliferation and liver carcinogenesis through the activation of PI3 Kinase and Akt.
In pilot transaction studies and in vitro kinase assays I have obtained compelling data suggesting that E2 is a novel member of the actin-regulating kinase family (Ark/Prk kinases) that associates physically with, and phosphorylates AP50 on its phospho-acceptor Thr156, a key step for clathrin-mediated endocytosis (25,50,73). Also, we have shown that E2 is associated with AP50 in livers from HCV-infected patients, and that AP50 is phosphorylated on Thr156 to a much greater extent in these livers.
In preliminary studies, we have also found that E2, in the absence of extracellular growth factors, increases PIP2, PI3K, PDK1 and Akt, as well as their activities. This signaling cascade promotes proliferation. Moreover, HCV E2 markedly stimulates hepatocyte DNA replication to an even greater extent than classic tumor promoters TGF( and EGF.
1. The physiological relevance of the interaction between HCV E2 and AP50 and the phosphorylation of AP50 in a unique HCV infection system of primary human hepatocytes. We will analyze the protein motifs of E2 which are indispensable for association with and phosphorylation of AP50 in the HCV Huh-7 infection system.
2. The effects of HCV E2 on proliferation in HCV infected primary human hepatocyte cultures and in the HCV Huh-7 infection system.
These recently characterized HCV E2 mechanisms have yet to be explored in an HCV-infected normal primary human hepatocyte model system. This will be an extremely valuable model to study these intriguing HCV E2 mechanisms, and possibly others, in the presence of the entire, naturally occurring HCV viral particle with a complete life cycle, obtained directly from patients. Mutational analysis in the Huh-7 HCV infection system is necessary in order to investigate the roles of the individual motifs of E2 and their importance in HCV infection. In addition, the discovery and mechanistic studies of a novel viral kinase has extensive implications in the fields of HCV, general virology, clathrin-mediated endocytosis, and signal transduction.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TREATMENT OF LIVER INJURY AND FIBROSIS: SAFETY PHARMACOLOGY AND TOXICOLOGY
-
批准号:10095347
-
项目类别:
-
资助金额:$113.61万
-
财政年份:2019
-
负责人:MARTINA BUCK
-
依托单位:
TREATMENT OF LUNG FIBROSIS : IND PHARMACOLOGY AND TOXICOLOGY
-
批准号:10026462
-
项目类别:
-
资助金额:$132.7万
-
财政年份:2019
-
负责人:MARTINA BUCK
-
依托单位:
Targeting C/EBP-beta Phosphorylation for the Treatment of Lung Fibrosis
-
批准号:8904981
-
项目类别:
-
资助金额:$31.61万
-
财政年份:2015
-
负责人:MARTINA BUCK
-
依托单位:
C/EBP-beta PEPTIDES FOR THE TREATMENT OF LUNG INJURY AND FIBROSIS
-
批准号:8779048
-
项目类别:
-
资助金额:$31.18万
-
财政年份:2014
-
负责人:MARTINA BUCK
-
依托单位:
C/EBP-beta PEPTIDES FOR THE TREATMENT OF LIVER INJURY AND FIBROSIS
-
批准号:8592994
-
项目类别:
-
资助金额:$30.69万
-
财政年份:2013
-
负责人:MARTINA BUCK
-
依托单位:
Hepatitis C: E2 Molecular Mechanisms
-
批准号:7887884
-
项目类别:
-
资助金额:$35.4万
-
财政年份:2010
-
负责人:MARTINA BUCK
-
依托单位:
Hepatitis C: E2 Molecular Mechanisms
-
批准号:8322071
-
项目类别:
-
资助金额:$29.09万
-
财政年份:2010
-
负责人:MARTINA BUCK
-
依托单位:
Hepatitis C: E2 Molecular Mechanisms
-
批准号:8663241
-
项目类别:
-
资助金额:$29.09万
-
财政年份:2010
-
负责人:MARTINA BUCK
-
依托单位:
Hepatitis C: E2 Molecular Mechanisms
-
批准号:8497680
-
项目类别:
-
资助金额:$28.07万
-
财政年份:2010
-
负责人:MARTINA BUCK
-
依托单位:
Hepatitis C: E2 Molecular Mechanisms
-
批准号:8198487
-
项目类别:
-
资助金额:$3.96万
-
财政年份:2010
-
负责人:MARTINA BUCK
-
依托单位:
Hepatitis C: E2 Molecular Mechanisms
-
批准号:8071218
-
项目类别:
-
资助金额:$29.69万
-
财政年份:2010
-
负责人:MARTINA BUCK
-
依托单位:
C/EBP beta Peptides for the Treatment of Hepatic Fibrosis
-
批准号:7941877
-
项目类别:
-
资助金额:$40.91万
-
财政年份:2009
-
负责人:MARTINA BUCK
-
依托单位:
C/EBP beta Peptides for the Treatment of Hepatic Fibrosis
-
批准号:7832282
-
项目类别:
-
资助金额:$46.75万
-
财政年份:2009
-
负责人:MARTINA BUCK
-
依托单位:
HEPATOCELLULAR CARCINOMA AND HEPATITIS C: E2 MOLECULAR MECHANISMS
-
批准号:7628592
-
项目类别:
-
资助金额:$14.88万
-
财政年份:2008
-
负责人:MARTINA BUCK
-
依托单位:
INFECTION AND REPLICATION OF NATURALLY OCCURRING HEPATITIS C VIRUS
-
批准号:7722452
-
项目类别:
-
资助金额:$0.2万
-
财政年份:2008
-
负责人:MARTINA BUCK
-
依托单位:
HEPATOCELLULAR CARCINOMA AND HEPATITIS C: E2 MOLECULAR MECHANISMS
-
批准号:7933355
-
项目类别:
-
资助金额:$4.54万
-
财政年份:2008
-
负责人:MARTINA BUCK
-
依托单位:
HEPATOCELLULAR CARCINOMA AND HEPATITIS C: E2 MOLECULAR MECHANISMS
-
批准号:7851359
-
项目类别:
-
资助金额:$14.88万
-
财政年份:2008
-
负责人:MARTINA BUCK
-
依托单位:
HEPATIC CARCINOGENESIS: MOLECULAR MECHANISMS
-
批准号:6663736
-
项目类别:
-
资助金额:$11.67万
-
财政年份:2002
-
负责人:MARTINA BUCK
-
依托单位:
HEPATIC CARCINOGENESIS: MOLECULAR MECHANISMS
-
批准号:6530519
-
项目类别:
-
资助金额:$11.41万
-
财政年份:2002
-
负责人:MARTINA BUCK
-
依托单位:
HEPATIC CARCINOGENESIS: MOLECULAR MECHANISMS
-
批准号:6930419
-
项目类别:
-
资助金额:$14.88万
-
财政年份:2002
-
负责人:MARTINA BUCK
-
依托单位:
海外基金